×

Biotech and Pharmaceuticals Medicine

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter. Tesaro is not actively exploring a sale, the people said this week, noting that there is a significant gap over the company's valuation between Tesaro and...

  • The company forecast 2017 hepatitis C drug sales of $7.5 billion- $9 billion, much lower than the $12 billion Wall Street analysts had expected, due to fewer patients starting on treatments and increased competition. Gilead's hepatitis C drugs Sovaldi and Harvoni revolutionized treatment of the serious liver disease, helping triple the company's sales to...

  • TOLEDO, Ohio— Shawn Blazsek knew a string of concussions from high school football and boxing was catching up with him. He would go days without sleeping and was forgetting how to tie his shoes. Still, at age 33, he was stunned after being told he had Alzheimer's disease.

  • The company forecast 2017 hepatitis C drug sales of $7.5 billion to $9 billion, much lower than the $12 billion Wall Street had expected. "The 2017 guidance was $4- $5 billion lower than buyside expectations," said RBC Capital Markets analyst Michael Yee, adding that the sales outlook implies 2017 earnings for Gilead of $6.60- $9.00 per share, which is well below the...

  • The company said it expects 2017 hepatitis C drug sales of $7.5 billion to $9 billion, much lower than the $12 billion Wall Street analysts had expected, as compiled by Evercore ISI. "The 2017 guidance was $4- $5 billion lower than buyside expectations," said RBC Capital Markets analyst Michael Yee, adding that the sales outlook suggests 2017 earnings for Gilead of...

  • Feb 7- The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday. The drug, etelcalcetide, will be sold under the brand name Parsabiv, Amgen said, adding that it is the first new therapy approved for the...

  • The company said it expects 2017 hepatitis C drug sales of $7.5 billion to $9 billion- much lower than the $12 billion Wall Street analysts had expected, as compiled by Evercore ISI. "The 2017 guidance was $4- $5 billion lower than buyside expectations and implied EPS 20-30 percent lower than consensus," said RBC Capital Markets analyst Michael Yee.

  • Following approval from the Food and Drug Administration, Phase I clinical trials will start in the first half of this year, the company said on Monday. Its first such "off-the-shelf" cell therapy UCART19, which is being developed with Servier and Pfizer, is now being tested in Phase I trials in Britain for acute lymphoblastic leukaemia and chronic lymphocytic...

  • Feb 6- Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon. The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court.

  • Feb 6- Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon. The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court.

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. For 2017, Amgen forecast adjusted earnings of $11.80 to $12.60 per share, with a midpoint below Wall Street estimates of...

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. For 2017, Amgen forecast adjusted earnings of $11.80 to $12.60 per share, with a midpoint below Wall Street estimates of...

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. The world's largest biotechnology company said net profit in the latest quarter rose to $1.94 billion, or $2.59 per share,...

  • Feb 2- The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy,...

  • *Q4 core EPS $1.21 vs consensus forecast $1.13. LONDON, Feb 2- AstraZeneca warned on Thursday that profit and revenue would both fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales. Chief Executive Pascal Soriot reaffirmed his confidence in the trial, despite recent mixed developments in the hotly contested cancer...

  • ZURICH, Feb 1- Roche is looking to expand its $2 billion- per-year diabetes business, not sell it or spin it off. Sales of Roche's diabetes products in 2016 slipped 4 percent to 2 billion Swiss francs, hurt by price pressure in the United States and extending a slide that began in 2015.. One bright spot for the business was Asia, where a 16 percent sales rise was primarily...

  • We will continue to invest in the US regardless of Trump: Roche CEO

    Roche CEO Severin Schwan discusses his strategy in the U.S. despite President Donald Trump's protectionism, as well as pricing pressures around the world.

  • Merck CEO: We had a great conversation with Trump

    Following the meeting between President Donald Trump and leaders in the pharmaceutical industry, Merck CEO Ken Frazier and other CEOs talk about their discussions.

  • Trump: I'll oppose anything that hurts competition for smaller players

    President Donald Trump meets with leaders in the pharmaceutical industry.